These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8086335)

  • 1. The transcription activation domains of v-Myc and VP16 interact with common factors required for cellular transformation and proliferation.
    Min S; Crider-Miller SJ; Taparowsky EJ
    Cell Growth Differ; 1994 Jun; 5(6):563-73. PubMed ID: 8086335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. v-Myc, but not Max, possesses domains that function in both transcription activation and cellular transformation.
    Min S; Taparowsky EJ
    Oncogene; 1992 Aug; 7(8):1531-40. PubMed ID: 1630816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective repression of myoD transcription by v-Myc prevents terminal differentiation of quail embryo myoblasts transformed by the MC29 strain of avian myelocytomatosis virus.
    La Rocca SA; Vannucchi S; Pompili M; Pinney DF; Emerson CP; Grossi M; Tatò F
    Oncogene; 2002 Jul; 21(31):4838-42. PubMed ID: 12101422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional analysis of the carboxy-terminal transforming region of v-Myc: binding to Max is necessary, but not sufficient, for cellular transformation.
    Min S; Mascarenhas NT; Taparowsky EJ
    Oncogene; 1993 Oct; 8(10):2691-701. PubMed ID: 8378081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeras of herpes simplex viral VP16 and jun are oncogenic.
    Schuur ER; Parker EJ; Vogt PK
    Cell Growth Differ; 1993 Sep; 4(9):761-8. PubMed ID: 8241024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The retinoblastoma susceptibility gene product regulates Myc-mediated transcription.
    Adnane J; Robbins PD
    Oncogene; 1995 Jan; 10(2):381-7. PubMed ID: 7838535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weak transcriptional activation is sufficient for transformation by v-Myb.
    Engelke U; Whittaker L; Lipsick JS
    Virology; 1995 Apr; 208(2):467-77. PubMed ID: 7747419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc.
    Fieber W; Schneider ML; Matt T; Kräutler B; Konrat R; Bister K
    J Mol Biol; 2001 Apr; 307(5):1395-410. PubMed ID: 11292350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1).
    Bader AG; Schneider ML; Bister K; Hartl M
    Oncogene; 2001 Nov; 20(51):7524-35. PubMed ID: 11709724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased tumorigenicity of c-Myc-transformed fibroblasts expressing active USF2.
    Choe C; Chen N; Sawadogo M
    Exp Cell Res; 2005 Jan; 302(1):1-10. PubMed ID: 15541720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of the structure and function of the chicken c-myc and v-myc genes: v-myc is a more potent inducer of cell proliferation and apoptosis than c-myc.
    Petropoulos CJ; Givol I; Hughes SH
    Oncogene; 1996 Jun; 12(12):2611-21. PubMed ID: 8700520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-terminal transcriptional activation domain of LZIP comprises two LxxLL motifs and the host cell factor-1 binding motif.
    Luciano RL; Wilson AC
    Proc Natl Acad Sci U S A; 2000 Sep; 97(20):10757-62. PubMed ID: 10984507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Myc inhibits myogenic differentiation and myoD expression by a mechanism which can be dissociated from cell transformation.
    La Rocca SA; Crouch DH; Gillespie DA
    Oncogene; 1994 Dec; 9(12):3499-508. PubMed ID: 7970710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artificial oncoproteins: modified versions of the yeast bZip protein GCN4 induce cellular transformation.
    Nishizawa M; Fu SL; Kataoka K; Vogt PK
    Oncogene; 2003 Sep; 22(39):7931-41. PubMed ID: 12970741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transformation of murine myelomonocytic cells by myc: point mutations in v-myc contribute synergistically to transforming potential.
    Symonds G; Hartshorn A; Kennewell A; O'Mara MA; Bruskin A; Bishop JM
    Oncogene; 1989 Mar; 4(3):285-94. PubMed ID: 2649846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc.
    Austen M; Cerni C; Lüscher-Firzlaff JM; Lüscher B
    Oncogene; 1998 Jul; 17(4):511-20. PubMed ID: 9696045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional cell transformation by doxycycline-controlled expression of the MC29 v-myc allele.
    Oberst C; Hartl M; Weiskirchen R; Bister K
    Virology; 1999 Jan; 253(2):193-207. PubMed ID: 9918878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional analysis of the N-terminal domain of the Myc oncoprotein.
    Oster SK; Mao DY; Kennedy J; Penn LZ
    Oncogene; 2003 Apr; 22(13):1998-2010. PubMed ID: 12673205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. v-Myc is invariably required to sustain rapid proliferation of infected cells but in stable cell lines becomes dispensable for other traits of the transformed phenotype.
    Tikhonenko AT; Black DJ; Linial ML
    Oncogene; 1995 Oct; 11(8):1499-508. PubMed ID: 7478574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crosstalk between Myc and activating transcription factor 2 (ATF2): Myc prolongs the half-life and induces phosphorylation of ATF2.
    Miethe J; Schwartz C; Wottrich K; Wenning D; Klempnauer KH
    Oncogene; 2001 Dec; 20(56):8116-24. PubMed ID: 11781825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.